ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 820,01
-0,11%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. GeoVax Labs Inc (GOVX)

  7. GeoVax Labs Inc (GOVX) Actualités

GOVX GeoVax Labs Inc

1,61
0,19 (13,38%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
GeoVax Labs Inc GOVX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,19 13,38% 1,61 06:00:05
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,42 1,42 1,70 1,61 1,42
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
04/4/202418:30GLOBEGeoVax Presents Data on GEO-CM04S1, a Next Generation..
28/3/202414:00GLOBEGeoVax to Present Data on GEO-CM04S1, a Next Generation..
12/3/202414:00GLOBEGeoVax to Present at the 36th Annual Roth Conference
11/3/202421:13EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
11/3/202405:15EDGAR2Form EFFECT - Notice of Effectiveness
06/3/202415:00GLOBEGeoVax Achieves Milestone in Transition to Commercially..
01/3/202422:08EDGAR2Form S-3 - Registration statement under Securities Act of..
29/2/202422:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202422:00GLOBEGeoVax Reports 2023 Year-End Financial Results and Provides..
22/2/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202415:00GLOBEGeoVax to Report 2023 Financial Results and Provide..
19/2/202415:00GLOBEGeoVax to Present at the 2024 BIO CEO & Investor Conference
16/2/202422:01EDGAR2Form 8-K - Current report
14/2/202421:38EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/2/202415:00GLOBEGeoVax Announces Multiple Patent Issuances and Allowances
07/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202415:00GLOBEGeoVax Reports Positive Interim Data From Phase 2 Clinical..
31/1/202419:13EDGAR2Form 8-K - Current report
29/1/202415:00GLOBEGeoVax Announces 1-for-15 Reverse Stock Split to Regain..
16/1/202422:03EDGAR2Form 8-K - Current report
12/1/202422:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/1/202415:00GLOBEGeoVax Appoints Dr. Marc Pipas as Executive Medical..
04/1/202415:00GLOBEGeoVax Announces Gedeptin® Patient Enrollment Closure for..
03/1/202415:00GLOBEGeoVax Announces Issuance of Malaria Vaccine Patent
02/1/202422:10EDGAR2Form S-1 - General form for registration of securities under..
27/12/202315:00GLOBEGeoVax to Present at Biotech Showcase During J.P. Morgan..
26/12/202321:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:00GLOBEGeoVax Expands Rights Under NIH COVID-19 License to Include..
08/12/202322:02EDGAR2Form 8-K - Current report
04/12/202314:00EDGAR2Form 8-K - Current report
30/11/202322:30GLOBEGeoVax Hemorrhagic Fever Vaccine Data Presented at World..
29/11/202315:00GLOBEGeoVax to Participate in Upcoming December Investor Events
28/11/202315:00GLOBEGeoVax COVID-19 Vaccine Clinical Data Presented at World..
27/11/202322:06EDGAR2Form DEF 14A - Other definitive proxy statements
17/11/202322:27EDGAR2Form PRE 14A - Other preliminary proxy statements
14/11/202315:00GLOBEProgress on GeoVax’s Universal Coronavirus Vaccine..
09/11/202318:40EDGAR2Form 8-K - Current report
08/11/202322:04EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/11/202322:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/11/202322:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08/11/202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:00GLOBEGeoVax Reports Third Quarter 2023 Financial Results and..
31/10/202314:00GLOBEGeoVax to Report Third Quarter 2023 Financial Results and..
30/10/202314:00GLOBEGeoVax Commences Site Expansion for Phase 2 Trial of..
25/10/202315:00GLOBEGeoVax to Participate in Upcoming November Investor and..
24/10/202315:00GLOBEGeoVax Update: Clinical and Operational Progress Toward..
09/10/202315:00GLOBEGeoVax Receives Notice of Allowance for Marburg Vaccine..
05/10/202315:00GLOBEGeoVax Receives Notice of Allowance for HIV Vaccine Patent
27/9/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/9/202315:00GLOBEGeoVax to Participate in Upcoming October Investor and..

Dernières Valeurs Consultées

NASDAQ
GOVX
GeoVax Labs
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés